

## Product datasheet

### AAV9 VP2, recombinant protein

#### Short overview

<b>Cat. No.</b>	640843
<b>Quantity</b>	10 µg
<b>Concentration</b>	100 µg/ml (1.45 µM)

#### Product description

<b>Formulation</b>	Liquid, 6 M urea in PBS
<b>Source</b>	Escherichia coli
<b>Molecular Weight</b>	68.6 kDa (calculated Mw from aa sequence)
<b>Purity</b>	> 95% (determined by SDS PAGE)
<b>Product description</b>	N-terminal His-tagged (MGSSHHHHHSSGLVPRGSH) recombinant AAV9 capsid protein VP2
<b>Purification</b>	Ni-NTA chromatography
<b>Storage</b>	-80°C
<b>Intended use</b>	Research use only
<b>Application</b>	Dot blot, SDS PAGE, WB

#### Applications

<b>Dot Blot</b>	100 ng, depending on primary antibody and detection method
<b>SDS PAGE</b>	1 µg
<b>Western Blot (WB)</b>	5-20 ng, depending on primary antibody and detection method


#### Background

The AAV capsid consists of three capsid proteins, i.e. VP1, VP2 and VP3, which differ in their N-terminus and encapsulate the genomic ssDNA. In native virus particles, the three proteins form subunits with a ratio of 1:1:10 (VP1:VP2:VP3), in a total number of 60 subunits per capsid. The recombinant AAV9 VP2 protein in combination with recombinant AAV9 VP1 (Cat. No. 640842) and recombinant AAV9 VP3 (Cat. No. 640844) can be used to create a mixture with the precise molar ratio of 1:1:10 to compare the protein composition of the viral capsid in your sample by protein detection methods, e.g. western blot. All three recombinant AAV9 capsid proteins are available as a set (Cat. No. 72009) or as individual proteins (Cat. No. 640842, 640843, 640844). Note: please find an example how to prepare western blot samples in the pipetting scheme below. Aliquots of the remaining samples can be stored at -80°C for reuse.


#### Product images



AAV9 VP2, recombinant protein



SDS PAGE analysis to evaluate the purity of the AAV9 VP2 (Cat. No. 640843). To perform SDS PAGE analysis, 1 µg of protein was diluted in 10 µl PBS and sample buffer and denatured at 95°C for 5 min. The sample was loaded onto a 4-20% gradient gel (40 min at 200 V). Afterwards, the gel was stained for 1 h at RT with Coomassie solution and destained with water. The purity of AAV9 VP2 is > 95%.



Western blot analysis of recombinant AAV2 VP proteins (Cat. No. 72001), recombinant AAV5 VP proteins (Cat. No. 72005), recombinant AAV6 VP proteins (Cat. No. 72006), recombinant AAV8 VP proteins (Cat. No. 72008) and recombinant AAV9 VP proteins (Cat. No. 72009) with B1 antibody (Cat. No. 690058). Western blot analysis was performed on the precise molar ratio of 1:1:10 (13.5 ng VP1:11 ng VP2:100 ng VP3) combined in one lane. The PVDF membrane was blocked with 5% milk in PBST for 1 h at RT. The primary antibody anti-AAV VP1/VP2/VP3, B1 (Cat. No. 690058) was diluted in blocking buffer (antibody concentration 500 ng/ml) and incubated for 1 h at RT. The secondary antibody anti-mouse IgG HRP was also diluted in blocking buffer (antibody concentration 200 ng/ml) and incubated for 1 h at RT. The bands were visualized by chemiluminescent detection using Pierce ECL Western Blotting Substrate.